

## FOR IMMEDIATE RELEASE

**TO: COMPANY ANNOUNCEMENTS OFFICE  
ASX LIMITED**

**DATE: 24 March 2016**

---

### **SECOS EXPANDS US PATENT POSITION**

- United States Patent and Trademark Office grants patent for Cardia Biohybrid™ resin in foam applications
- Cardia expands patent portfolio to twenty patents granted with forty one more pending registration
- Intellectual Property underpins commercially successful Cardia Compostable and Biohybrid™ product ranges
- Cardia capitalises on growth of bioplastics with leading brand owners where strong intellectual property position is a key requirement



SECOS Group Limited (ASX: SES) is pleased to announce that Cardia Bioplastics, its wholly owned subsidiary, has secured patent protection for its Cardia Biohybrid™ foam products and processes from the United States Patent and Trademark Office. The U.S. patent 9,255,197 was granted for Cardia's unique and innovative Biohybrid™ resin formulations tailored to protective packaging foam applications.

This new corner stone patent expands Cardia Bioplastics growing intellectual property portfolio of 11 patent families, with 20 patents so far granted in USA, Europe, Australia, China, Japan, New Zealand

For personal use only

and South Africa. The patents protect the composition formulation and manufacturing process invented by Cardia's R&D team.

On receiving the news, Dr. Frank Glatz, Chief Executive Officer of Cardia Bioplastics said, "This marks an important milestone for Cardia Bioplastics as granted patents further support the technical differentiation of our Cardia Biohybrid™ and Compostable product offering and protect the intellectual property of the Company."

"Cardia is collaborating with leading global brand owners to reduce the environmental impact of their packaging. Cardia's Biohybrid™ technology enables them to reduce the carbon footprint and the use of less oil in their packaging with an environmental benefit whilst maintaining product performance. Cardia's strong patent position and freedom to operate is a critical requirement for these large global brand owners."

Richard Tegoni SECOS Group Chairman stated, "Protecting Cardia's intellectual property is a high priority as it supports our businesses long-term growth strategy of creating new Compostable and Biohybrid™ resins that meet the needs of the growing market for resins and finished products."

The continual expansion of Cardia's patent portfolio validates Cardia's technical capabilities and unique formulation. With rapid global growth of bioplastics use in diverse product applications, Cardia's patent portfolio capitalizes on the demand of leading brand owners where strong intellectual property position is a key requirement.

---

For more information please contact:

Mr Richard Tegoni  
Executive Chairman  
SECOS Group Limited  
(614) 11110901

### **About SECOS**

SECOS (ASX code SES) was formed in April 2015 by the merger of the business operations of Cardia Bioplastics Limited, a company listed on the ASX, and the Stellar Films Group of companies. .

SECOS' core business is the manufacture of sustainable resins and films for specific core markets comprising:

1. Sustainable films and packaging products targeting the hygiene sector; and
2. Sustainable waste management solutions.

SECOS' current operations include:

1. Manufacturing plants in Australia, Malaysia and China – all strategically located to support SECOS' target markets;



*Changing the world of packaging*

2. A global sales and distribution network with a presence in 27 countries;
3. Strong intellectual property and patent position on technology and comprehensive range of high performance sustainable products; and
4. A highly focused management team with internationally recognized industry expertise in sustainable packaging.

For personal use only